This trial is active, not recruiting.

Conditions bifurcation lesions, coronary artery
Treatment drug-eluting balloon
Phase phase 3
Sponsor Liaoning Biomedical Materials R&D Center Co., Ltd.
Start date December 2014
End date December 2015
Trial identifier NCT02325817, Bifurcation


The purpose is to observe and evaluate the safety and efficacy of drug-eluting balloon in the treatment of patients with bifurcation lesions of coronary artery.

Note: the drug-eluting balloons are manufactured and supported by Liaoning Biomedical Materials R&D Center Co., Ltd. (LBC).

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification safety/efficacy study
Intervention model parallel assignment
Masking open label
Primary purpose treatment
drug-eluting balloon
(Active Comparator)
drug-eluting balloon

Primary Outcomes

Target lesion Stenosis (diameter, %)
time frame: 270-day

Eligibility Criteria

Male or female participants from 18 years up to 80 years old.

Inclusion Criteria: 1. Male or non-pregnant female ages 18-80 years old 2. Patients with asymptomatic myocardial ischemia symptom, stable or unstable angina pectoris or old myocardial infarction 3. Patients with bifurcation lesions of coronary artery observed by angiography. 4. The main branch of the vessels are suitable for PCI and stent therapy, and the side branch are intended to implement the kissing dilatation without considering dual stent implantation. 5. De Novo bifurcation lesions and diameter stenosis are not less than70%; 6. Referenced vessel diameters range from 1.25mm to 5.0mm, and lesions range are not more than 40mm 7. Residual stenosis are not more than 50% after predilatation; 8. Patients who understand the purpose of this trial, voluntary and sign informed consent. Exclusion Criteria: 1. Heavily calcified lesions which cannot be dalatated successfully, and the lesions which are not suitable by balloon angioplasty 2. Left main coronary artery lesions without protection or related bifurcation lesions 3. Patients with severe heart failure symptoms (above NYHA III) or Left ventricular ejection fraction (LVEF) below 35% (ultrasound or left ventricular angiography) 4. Impairment of the renal function preoperative: Serum creatinine above 2.0mg/dl; 5. Patients with hemorrhagic tendency, the history of active digestive ulcers, the history of subarachnoid hemorrhage cerebral hemorrhage, antiplatelet and anticoagulant therapy contraindication and unable to anticoagulant therapy; 6. Patients who are allergic to aspirin, ticagrelor, clopidogrel, ticlopidine, heparin, contrast agent and paclitaxel, and cannot 1-year tolerate dual antiplatelet therapy (aspirin + clopidogrel or ticagrelor) 7. Patients whose expected lives are less than 1 year; 8. Patients who are considered to have poor compliance and cannot complete the trial in accordance with requirements. 9. In-stent restenosis lesions 10. Patients who are enrolled in this trial and need stent therapy due to vascular laceration or severe stenosis, and those patients are calculated as fall off cases.

Trial information was received from ClinicalTrials.gov and was last updated in December 2014.
Information provided to ClinicalTrials.gov by Liaoning Biomedical Materials R&D Center Co., Ltd..